Eric Easom is an American businessman and entrepreneur. He leads one of the most promising therapeutic research and development biotech companies in the United States today. When we heard about AN2 Therapeutics we wanted to know more about the company, its mission, and its leadership. We discovered that Eric Easom is the chief executive officer, standing at the helm. Mr. Easom has carved a niche in the industry, picking up a host of impressive skills along the way, leading the therapeutics organization to a productive stage. Here are ten things we learned about him that you probably didn’t know, but might find inspiring.
1. Eric Easom is co-founder of AN2 Therapeutics
According to Crunchbase, Easom is not only the CEO of An2 Therapeutics, but he is also one of the co-founders of the business. He is part-owner of the Menlo Park startup that is making business news. He partnered with George Talbot, Michael Alley, and Joseph Zakrzewski to launch research, development, and testing of potential cures and treatments for serious infectious illnesses. They started the operation on January 1, 2017. He accepted the job of CEO from the inception of the company.
2. He has more than one full-time job
The Org reports that Eric Easom serves multiple roles at AN2 Therapeutics. He leads the executive team as Chief Executive Officer. He is also the President of the company. His third job at AN2 Therapeutics is as a member of the board of directors. He is busy juggling multiple roles but he does it with proficiency. Easom has a solid background in leadership and his talents have helped to lead the company to its current level of success.
3. Eric Easom has nearly three decades of leadership experience in biotech and pharmaceuticals
Eric is going on his fifth year as leader of AN2 Therapeutics, but this is just one of the experiences in his repertoire in the biotech and pharmaceuticals industry. Over the past 29 years, he served as a leader in Anacor Pharmaceuticals for nine years. He served on the board of directors for Resilient Biotics and the Chagas Disease Foundation. He advised the California Life Sciences Institute and worked with numerous trusts, foundations, and university programs.
4. His focus is on meeting unmet needs in the infectious disease discipline
Eric Easom has dedicated much of his career to promoting meaningful discoveries for treatments and cures for infectious diseases that have previously been unmet or neglected. Teams under his leadership have discovered effective medicines to treat infectious diseases in the developing works. Some of them include obscure health conditions such as leishmaniasis, African sleeping sickness, trypanosome diseases such as Chagas disease, river blindness, cryptosporidiosis, malaria, and numerous other diseases. He worked with the Global Alliance for Veterinary Medicine, the Drugs for Neglected Diseases initiative, the Global Anti Wolbachia Consortium, the London School of Hygiene and Tropical Medicine, and others.
5. His forte is in resaerch
Our query into Eric Easom’s career portfolio revealed that he has spent years building research and development programs. He formed close partnerships with numerous research organizations and helped them by providing advisement, leadership, and fundraising support. He’s worked with the Colorado State University’s Slayden and Lenaerts’ Labs, Walter Reed, the Croft Lab in London, England, and the Infectious Disease Research Institute.
6. Eric Easom’s academic degrees are in other disciplines
LinkedIn confirms that Eric Easom didn’t attend college in biotech or pharmaceuticals. He attended the University of Louisville from 1985 to 1989 in the electrical engineering program. He graduated with his bachelor of science in the discipline. He is an engineer. He continued with the University to earn a master’s in electrical engineering in 1990. He returned to school in 1995 at the Indian University’s Kelley School of Business where he earned his MBA in marketing and finance in 1997.
7. Eric Easom started his career at Eli Lilly & Co.
Easom was hired at the pharmaceutical giant Eli Lilly & Co in 1990 as a US Brand Manager for the Endocrine Business Unite and Humatrope. He served in the Corporate Business Development division from 1997 through 2000. From January 1995 through 1997, he worked in the Finance department. From August 1990 through December 1994, he served as an engineer in manufacturing. Eric wore many hats at Eli Lilly, but he also gained a lot of experience in multiple aspects of the biotech and pharmaceutical industry.
8. He is a serial entrepreneur
AN2 Therapeutics is not the only company that Eric Easom established. In July of 2003, he founded Hope Pharmaceuticals. He served as chief executive officer of the company. His goal at Hope Pharmaceuticals was to launch an initiative to establish a company in the biotech industry that would be sustainable. Additionally, the organization’s energies would focus on discovery through research, as well as development, then sales for treatments that focus on unmet needs in the medical field. His goal was to find treatments and cures for infectious diseases affecting people on a global scale.
9. He worked in marketing and business development
Eric Easom has worked in many aspects of the biotech and pharmaceuticals industries. He worked at InteKrin Therapeutics as the senior director of business development and marketing from July 2007 through January 2009. He also worked at MedImmune as the director of marketing for a little over a year in 2007. His job was to oversee the business and marketing divisions of the companies.
10. Eric Easom is a balanced professional
Part of the success of Eric Easom is his versatility and massive knowledge base. He’s worked for many biotech and pharmaceutical companies and organizations. His primary career focus started in engineering and business administration, but his exposure to the biotech and pharmaceuticals industries helped him to become an expert in what it takes to build such businesses up and make them successful. He also worked as a director of the pharmaceutical division of McKesson Medical-Surgical from 2005 to 2006. He found an industry that inspired a passion to find cures and treatments for diseases that had previously been neglected or overlooked. He knows the R&D end of the biotech business, but he also understands the importance of leadership that is mission-driven and goal-focused.